Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
128 hedge funds and large institutions have $432M invested in Orexigen Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 30 reducing their positions, and 21 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
1% less funds holding
Funds holding: 129 → 128 (-1)
19% less call options, than puts
Call options by funds: $8.43M | Put options by funds: $10.4M
25% less capital invested
Capital invested by funds: $579M → $432M (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18M |
| 2 |
SC
Samlyn Capital
New York
|
+$12.3M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$9.52M |
| 4 |
Morgan Stanley
New York
|
+$6.26M |
| 5 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
+$5.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$15M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$9.47M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$6.32M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$5.7M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3.62M |
OREX Hedge Fund Activity: Q3 2014 in Review
128 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q3 2014, worth a combined $432M — down 25% from $579M a quarter earlier.
Fund positioning in OREX was balanced in Q3 2014: 21 funds opened new positions, 21 closed out, 52 added to existing stakes and 30 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $18M. The largest seller was First Manhattan, cutting an estimated $15M.
- 128 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q3 2014, down from 129 in Q2 2014.
- Funds reported $432M of Orexigen Therapeutics, Inc. stock for Q3 2014, down 25% quarter-over-quarter.
- 21 funds opened new Orexigen Therapeutics, Inc. positions in Q3 2014 and 21 closed out, a net change of 0 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q3 2014 was T. Rowe Price Associates, an estimated $18M added.
- The largest Orexigen Therapeutics, Inc. seller in Q3 2014 was First Manhattan, an estimated $15M sold.
Based on aggregated 13F filings for Q3 2014.